



August 22, 2022

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE Prime Market)
Contact person: Kenji Yamada, Senior Vice President,
Corporate Administration Headquarters
(TEL. +81-3-6711-5200)

Japan Lifeline Expands Distribution Agreement With Wallaby-phenox For Neurovascular Products

Japan Lifeline Co., Ltd. (“Japan Lifeline” or “the Company”) is pleased to announce that it has concluded an updated exclusive Japanese distribution agreement with Wallaby Medical (HK) Limited (“Wallaby”) for the distributorship of 11 neurovascular treatment devices. The agreement is for a period of 10 years, beginning August 2022. The agreement also covers the embolic coil, which the Company launched last year.

Japan Lifeline has been successfully marketing Wallaby’s embolic coils for neurovascular cases since April 2022. The majority of the newly added 10 products are made by phenox GmbH (Germany) (“phenox”), which Wallaby’s parent company acquired in April 2022. phenox is a leading medical device company with a wide range of novel therapeutic devices in the neurovascular space selling in more than 45 countries, including the p64/p48 range of flow diverters for the treatment of intracranial aneurysms and the pRESET range of stent retrievers for the mechanical thrombectomy of ischemic strokes. Additionally, phenox has proprietary coating technologies for the enhancement of its permanent and short-term implants. With this agreement, Japan Lifeline will establish a top-class product lineup in Japan for the treatment of acute ischemic stroke and cerebral aneurysms, which are the main target diseases for neurovascular treatment today. (See attached “List of Products Subject to the Agreement”)

Acute ischemic stroke is a disease that occurs when a blood vessel in the brain becomes clogged with a blood clot. In recent years, endovascular treatment using catheters has rapidly become common for the treatment of acute ischemic stroke, with about 16,000 operations performed annually. The Company plans to launch four products in this area during the fiscal year ending March 2024, including an aspiration catheter and a stent retriever.

Cerebral aneurysm is a condition in which the walls of a cerebral artery swell to form a balloon-like shape, posing the risk of bleeding (subarachnoid hemorrhage). In addition to the embolic coil already launched, the Company plans to introduce cutting-edge treatment devices for this disease, such as flow diverters and stents for bifurcation aneurysms.

Japan Lifeline has developed expertise in sales and marketing of various devices that enable minimally invasive catheter-based treatment in the cardiovascular space. Leveraging these experiences and sales capabilities, the Company plans to fully enter the neurovascular space with Wallaby’s broad product lineup.

Japan Lifeline estimates the current market size for neurovascular treatment devices in Japan to be about 30 billion yen per year. It expects that the market will continue to grow as treatment using latest devices is still in the gradual expansion phase. By building a product portfolio that comprehensively covers the neurovascular space

and coping with the diverse needs of the medical professionals, the Company is eager to expand its presence in the important interventional neurovascular space and capture meaningful market share over the long term.

About Wallaby Medical

Wallaby is a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke. Wallaby acquired phenox, a German-based global neurovascular innovation and technology leader in April 2022. Wallaby and phenox together have a broad product portfolio covering both ischemic and hemorrhagic stroke as well as access and support. The key product lines include the Avenir® Coil System for treating intracranial aneurysms and other neurovascular abnormalities, the Esperance™ Aspiration Catheter for ischemic stroke treatment procedures, p64/p48 range of flow diverters for the treatment of intracranial aneurysms, and the pRESET range of stent retrievers for the mechanical thrombectomy of ischemic strokes. Additionally, phenox has proprietary coating technologies for the enhancement of its permanent and short-term implants. The products of Wallaby and phenox are marketed in over 50 countries worldwide based on internationally leading clinical data. For more information, visit www.wallabymedical.com and <https://phenox.net/international/>.

Attachment: List of Products Subject to the Agreement

Diseases	Products	Launch Schedule
Acute Ischemic Stroke	Aspiration Catheter	FYE March 2024
	Stent Retriever	FYE March 2024
	Balloon Guiding Catheter	FYE March 2024
	Microcatheter	FYE March 2024
	Guiding Sheath	FYE March 2025 or later
	Neuro PTA Balloon Catheter	FYE March 2025 or later
Cerebral Aneurysms	Embolic Coil	Launched in December 2021
	Stent Assist Device	FYE March 2027 or later
	Flow Diverter	FYE March 2028 or later
	Stent Assist Device for Bifurcation Aneurysms	FYE March 2027 or later
	Vasospasm Treatment Device	FYE March 2027 or later